Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $132.70 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $46.85 | 3 | $0 (2020) |
| Boston Scientific Corporation | $25.97 | 1 | $0 (2022) |
| Amgen Inc. | $23.01 | 1 | $0 (2018) |
| Neos Therapeutics, LP | $19.80 | 1 | $0 (2017) |
| Genentech USA, Inc. | $17.07 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $25.97 | 1 | Boston Scientific Corporation ($25.97) |
| 2020 | $16.15 | 1 | Merck Sharp & Dohme Corporation ($16.15) |
| 2018 | $70.78 | 4 | Merck Sharp & Dohme Corporation ($30.70) |
| 2017 | $19.80 | 1 | Neos Therapeutics, LP ($19.80) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/10/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: General - Pain Management_NMD | ||||||
| 01/23/2020 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, STEGLUJAN | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/21/2018 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Virology & Specialty Care | ||||||
| 07/31/2018 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, DULERA | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/17/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Cardiology | ||||||
| 02/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2017 | Neos Therapeutics, LP | Adzenys XR-ODT (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: ADHD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 556 | 815 | $105,932 | $36,038 |
| 2022 | 12 | 2,734 | 4,832 | $659,688 | $227,688 |
| 2021 | 20 | 3,017 | 5,313 | $591,262 | $231,345 |
| 2020 | 20 | 1,606 | 3,068 | $366,904 | $140,367 |
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 3 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 75 | 75 | $14,952 | $7,015 | 46.9% |
| 87486 | Detection test for chlamydia pneumoniae | Office | 2020 | 79 | 81 | $7,106 | $2,842 | 40.0% |
| 87581 | Detection test for mycoplasma pneumoniae (bacteria) | Office | 2020 | 79 | 81 | $7,106 | $2,842 | 40.0% |
| 87640 | Detection test for staphylococcus aureus (bacteria) | Office | 2020 | 79 | 81 | $7,118 | $2,842 | 39.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 59 | 60 | $3,351 | $2,145 | 64.0% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2020 | 15 | 15 | $1,918 | $1,885 | 98.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 94 | 149 | $3,593 | $1,337 | 37.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 24 | $2,321 | $1,111 | 47.8% |
| 71046 | X-ray of chest, 2 views | Office | 2020 | 25 | 26 | $1,499 | $618.17 | 41.2% |
| 87804 | Detection test for influenza virus | Office | 2020 | 19 | 38 | $1,305 | $589.20 | 45.2% |
| 87880 | Strep test (streptococcus, group a) | Office | 2020 | 12 | 12 | $466.16 | $180.18 | 38.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2020 | 52 | 208 | $5,200 | $77.92 | 1.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 15 | 16 | $800.00 | $47.94 | 6.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 63 | 570 | $14,250 | $43.70 | 0.3% |
| 81003 | Automated urinalysis test | Office | 2020 | 19 | 20 | $232.07 | $42.45 | 18.3% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2020 | 15 | 58 | $1,550 | $23.62 | 1.5% |
About Dr. Jason Junkins, M.D
Dr. Jason Junkins, M.D is a Internal Medicine healthcare provider based in Rainbow City, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114928512.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Junkins, M.D has received a total of $132.70 in payments from pharmaceutical and medical device companies, with $25.97 received in 2022. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($132.70).
As a Medicare-enrolled provider, Junkins has provided services to 7,913 Medicare beneficiaries, totaling 14,028 services with total Medicare billing of $635,437. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Rainbow City, AL
- Active Since 08/09/2005
- Last Updated 03/12/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1114928512
Products in Payments
- JANUVIA (Drug) $28.72
- General - Pain Management (Device) $25.97
- Repatha (Biological) $23.01
- Adzenys XR-ODT (Drug) $19.80
- KEYTRUDA (Biological) $18.13
- Xofluza (Drug) $17.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.